Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update

References

• FDA, XELJANZ Prescribing Information. 2020. [cited 2021 January 10] . Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213082s000lbl.pdf
   Google Scholar
• You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334–351.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Gadina M. Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol. 2019;15(2):74–75.
   PubMed Web of Science ®Google Scholar
• Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104(3):499–514.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960–1968.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7–18.
   PubMed Web of Science ®Google Scholar
• Brooks AJ, Dai W, O’Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014;344(6185):1249783.
   PubMed Web of Science ®Google Scholar
• Huang Z, Su Z, Song J, et al. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019;19(1):143.
   PubMedGoogle Scholar
• Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851.
   PubMed Web of Science ®Google Scholar
• Kerrigan SA, McInnes IB. JAK inhibitors in rheumatology: implications for paediatric syndromes? Curr Rheumatol Rep. 2018;20(12):83.
   PubMed Web of Science ®Google Scholar
• Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27(5):505–510.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, and Zuber Z, et al., Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017;15(1):86.
   PubMedGoogle Scholar
• Huber AM. Juvenile idiopathic inflammatory myopathies. Pediatr Clin North Am. 2018;65(4):739–756.
   PubMed Web of Science ®Google Scholar
• Kul Cinar O, Papadopoulou C, Pilkington CA. Treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2021;23(2):13.
   PubMed Web of Science ®Google Scholar
• Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732–736.
   PubMedGoogle Scholar
• Papadopoulou C, Hong Y, and Omoyinmi E, et al., Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8.
   PubMedGoogle Scholar
• Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford). 2021;60(4):1700–1707.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.
   PubMed Web of Science ®Google Scholar
• Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–1621.
   PubMedGoogle Scholar
• Wang A, Morgan GA, Paller AS, et al. Skin disease is more recalcitrant than muscle disease: a long-term prospective study of 184 children with juvenile dermatomyositis. J Am Acad Dermatol. 2021;84(6):1610–1618.
   PubMed Web of Science ®Google Scholar
• Gitiaux C, Latroche C, Weiss‐Gayet M, et al. Myogenic progenitor cells exhibit type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis. Arthritis Rheumatol. 2018;70(1):134–145.
   PubMed Web of Science ®Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.
   PubMed Web of Science ®Google Scholar
• Hornig J, Weinhage T, Schmidt LH, et al. Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol. 2018;77(10):952–957.
   PubMed Web of Science ®Google Scholar
• Hornung T, Janzen V, Heidgen F-J, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537–2538.
   PubMed Web of Science ®Google Scholar
• Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–945.
   PubMed Web of Science ®Google Scholar
• Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases. J Autoimmun. 2019;100:131–136.
   PubMed Web of Science ®Google Scholar
• Paik JJ, Casciola‐Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858–865.
   PubMed Web of Science ®Google Scholar
• Ding Y, Huang B, Wang Y, et al. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis. 2020;80(4):543–545.
   Web of Science ®Google Scholar
• Aeschlimann FA, Frémond M-L, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80.
   PubMedGoogle Scholar
• Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70–e78.
   PubMed Web of Science ®Google Scholar
• Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.
   PubMedGoogle Scholar
• Landon-Cardinal O, Benveniste O, Allenbach Y. Reply: treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e60.
   PubMedGoogle Scholar
• Sözeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology (Oxford). 2020;59(12):e140–e141.
   PubMed Web of Science ®Google Scholar
• Valenzuela A, Chung L, Casciola-Rosen L, et al. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 2014;150(7):724–729.
   PubMed Web of Science ®Google Scholar
• Kim H, Dill S, and O'Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2020 Online ahead of print.
   Web of Science ®Google Scholar
• Voyer TL, Gitiaux C, and Authier F-J, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford). 202160(12):5801-5808.
   Google Scholar
• Heinen A, Schnabel A, Brück N, et al. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology (Oxford). 2021;60(4):e136–e138.
   PubMed Web of Science ®Google Scholar
• Cohen S, Radominski SC, Gomez‐Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(11):2924–2937.
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114–2119.
   PubMed Web of Science ®Google Scholar
• Pineles D, Valente A, Warren B, et al. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011;20(11):1187–1192.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Aguiar F, Rodrigues M, et al. Clinical phenotype and outcome in lupus according to age: a comparison between juvenile and adult onset. Reumatol Clin (Engl Ed). 2018;14(3):160–163.
   PubMed Web of Science ®Google Scholar
• Navallas M, Inarejos Clemente EJ, Iglesias E, et al. Connective tissue disorders in childhood: are they all the same? Radiographics. 2019;39(1):229–250.
   PubMed Web of Science ®Google Scholar
• Lattanzi B, Consolaro A, Solari N, et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: british isles lupus assessment group (BILAG), European consensus lupus activity measurement (ECLAM), systemic lupus activity measure (SLAM), systemic lupus erythematosus disease activity index (SLEDAI), physician’s global assessment of disease activity (MD global), and systemic lupus international collaborating clinics/American College of Rheumatology damage index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11(Suppl 11):S112–7.
   PubMedGoogle Scholar
• Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38(1):97–112.
   PubMed Web of Science ®Google Scholar
• Chan ES, Herlitz LC, Jabbari A. Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model. J Invest Dermatol. 2015;135(7):1912–1915.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41.
   PubMedGoogle Scholar
• Klaeschen AS, Wolf D, Brossart P, et al. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Exp Dermatol. 2017;26(8):728–730.
   PubMed Web of Science ®Google Scholar
• Dörner T, Tanaka Y, and Petri M, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med. 2020; 7(1):e000424.
   Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391.
   PubMed Web of Science ®Google Scholar
• Mazori DR, Min MS, Kassamali B, et al. Use of tofacitinib, 2%, ointment for periorbital discoid lupus erythematosus. JAMA Dermatol. 2021;157(7):880–882.
   PubMed Web of Science ®Google Scholar
• Briand C, Frémond M-L, Bessis D, et al. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis. 2019;78(3):431–433.
   PubMed Web of Science ®Google Scholar
• König N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468–472.
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Wolf C, Schwenke R, et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. 2019;155(3):342–346.
   PubMed Web of Science ®Google Scholar
• Pin A, Tesser A, and Pastore S, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020 20;21(20):7767.
   Web of Science ®Google Scholar
• Tüfekçi Ö, Bengoa Ş, Karapinar TH, et al. CANDLE syndrome: a recently described autoinflammatory syndrome. J Pediatr Hematol Oncol. 2015;37(4):296–299.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–518.
   PubMed Web of Science ®Google Scholar
• Frémond ML, Rodero MP, Jeremiah N, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138(6):1752–1755.
   PubMed Web of Science ®Google Scholar
• Sanchez GAM, Reinhardt A, and Ramsey S, et al., JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–3052.
   PubMed Web of Science ®Google Scholar
• Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104(2):364–373.
   PubMed Web of Science ®Google Scholar
• Torok KS. Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am. 2012;59(2):381–405.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213–218.
   PubMed Web of Science ®Google Scholar
• Kelsey CE, Torok KS. The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol. 2013;69(2):214–220.
   PubMed Web of Science ®Google Scholar
• Damsky W, Patel D, Garelli CJ, et al. Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea. J Invest Dermatol. 2020;140(7):1446–1449.e4.
   PubMed Web of Science ®Google Scholar
• Kim SR, Charos A, Damsky W, et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018;4(5):443–445.
   PubMedGoogle Scholar
• Soh HJ, Samuel C, Heaton V, et al. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. Rheumatol Int. 2019;39(5):933–941.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Incyte. Incyte announces U.S. FDA approval of Opzelura™ (ruxolitinib) cream, a topical JAK inhibitor, for the treatment of atopic dermatitis (AD). Press Release.[Cited 2021 Sept 21]; Available from: https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD/default.aspx
   Google Scholar
• Abbvie. U.S. FDA approves RINVOQ® (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis. Press Release [Cited 2022 Jan 14]; Available from: https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm#:~:text=14%2C%202022%20%2FPRNewswire%2F%20%2D%2D,treatment%20and%20is%20not%20well
   Google Scholar